TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth

Molecular Cancer Therapeutics

Volumn 6, Issue 12, 2007, Pages 3198-3207

  DeRosier, Leo Christopher ^a   Vickers, Selwyn M ^a   Zinn, Kurt R ^b   Huang, Zhi ^a   Wang, Wenquan ^b   Grizzle, William E ^d   Sellers, Jeffrey ^c   Stockard Jr , Cecil R ^d   Zhou, Tong ^b   Oliver, Patsy G ^c   Arnoletti, Pablo ^a   LoBuglio, Albert F ^b   Buchsbaum, Donald J ^c,e  

^a Kentucky   (United States)

^b University of Alabama at Birmingham   (United States)

^c The University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 5; DEATH RECEPTOR 5; GEMCITABINE; MONOCLONAL ANTIBODY; TRA 8 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ECHOGRAPHY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MICE; MICE, SCID; PANCREATIC NEOPLASMS;

EID: 37549019355     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0299     Document Type: Article

References (50)

1. American Cancer Society. Cancer facts and figures, 2007. http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2007.asp.
2. Ahmad NA, Lewis JD, Ginsberg GG, et al. Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol 2001;96:2609-15.
3. van Geenen RC, van Gulik TM, Offerhaus GJ, et al. Survival after pancreaticoduodenectomy for periampullary adenocarcinoma: an update. Eur J Surg Oncol 2001;27:549-57.
4. Billingsley KG, Hur K, Henderson WG, et al. Outcome after pancreaticoduodenectomy for periampullary cancer: an analysis from the Veterans Affairs National Surgical Quality Improvement Program. J Gastrointest Surg 2003;7:484-91.
5. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
6. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270-5.
7. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-83.
8. Di Costanzo F, Carlini P, Doni L, et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian Oncology Group for Clinical Research (GOIRC). Br J Cancer 2005;93:185-9.
9. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-16.
10. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033-40.
11. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. In: American Society of Clinical Oncology, 2005 Gastrointestinal Cancers Symposium; 2005;Miami, FL;2005.
12. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
13. Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90.
14. MacFarlane M, Ahmad M, Srinivasula SM, et al. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997;272:25417-20.
15. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3.
16. Rudner J, Jendrossek V, Lauber K, et al. Type I and type II reactions in TRAIL-induced apoptosis - results from dose-response studies. Oncogene 2005;24:130-40.
17. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3 - like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-27.
18. Stennicke HR, Jurgensmeier JM, Shin H, et al. Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem 1998;273:27084-90.
19. Kischkel FC, Lawrence DA, Tinel A, et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 2001;276:46639-46.
20. Lacour S, Hammann A, Wotawa A, et al. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001;61:1645-51.
21. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89.
22. Saleh A, Srinivasula SM, Acharya S, Fishel R, Alnemri ES. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem 1999;274:17941-5.
23. Wei MC, Lindsten T, Mootha VK, et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 2000;14:2060-71.
24. Kandasamy K, Srinivasula SM, Alnemri ES, et al. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor - related apoptosis-inducing ligand (TRAIL) - induced mitochondrial disruption and apoptosis: Differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res 2003;63:1712-21.
25. Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel antihuman DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001;7:954-60.
26. Satoh K, Kaneko K, Hirota M, et al. Tumor necrosis factor - related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas 2001;23:251-8.
27. Ozawa F, Friess H, Kleeff J, et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett 2001;163:71-81.
28. Xu ZW, Kleeff J, Friess H, Buchler MW, Solioz M. Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Res 2003;23:251-8.
29. Hylander BL, Pitoniak R, Penetrante RB, et al. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 2005;3:22.
30. Buchsbaum DJ, Zhou T, LoBuglio AF. TRAIL receptor-targeted therapy. Future Oncol 2006;2:493-508.
31. Straughn JM, Jr., Oliver PG, Zhou T, et al. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol 2006;101:46-54.
32. Fidler IJ, Wilmanns C, Staroselsky A, et al. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev 1994;13:209-22.
33. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998;17:279-84.
34. Capella G, Farre L, Villanueva A, et al. Orthotopic models of human pancreatic cancer. Ann N Y Acad Sci 1999;880:103-9.
35. Hotz HG, Reber HA, Hotz B, et al. An improved clinical model of orthotopic pancreatic cancer in immunocompetent Lewis rats. Pancreas 2001;22:113-21.
36. Stephan S, Datta K, Wang E, et al. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res 2004;10:6993-7000.
37. Yezhelyev MV, Koehl G, Guba M, et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 2004;10:8028-36.
38. Jaffee EM, Schutte M, Gossett J, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 1998;4:194-203.
39. Burdick MD, Harris A, Reid CJ, Iwamura T, Hollingsworth MA. Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines. J Biol Chem 1997;272:24198-202.
40. Grizzle WE, Myers RB, Manne U, Srivastava S. Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia. In: Hanausek M, Walaszek Z, editors. John Walker's methods in molecular medicine - tumor marker protocols. Totowa NJ: Humana Press, Inc.; 1998. p. 143-60.
41. Grizzle WE, Myers RB, Manne U, et al. Factors affecting immunohistochemical evaluation of biomarker expression in neoplasia. In: Hanausek M, Walaszek Z, editors. John Walker's methods in molecular medicine - tumor marker protocols. Totowa: Humana Press, Inc.; 1998. p. 161-79.
42. Poczatek RB, Myers RB, Manne U, et al. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 1999;162:1462-6.
43. Buchsbaum DJ, Zhou T, Grizzle WE, et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003;9:3731-41.
44. Crouch SP, Kozlowski R, Slater KJ, Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods 1993;160:81-8.
45. Petty RD, Sutherland LA, Hunter EM, Cree IA. Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin 1995;10:29-34.
46. Rodbard D. Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays. Clin Chem 1974;20:1255-70.
47. DeLean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioli gand assay, and physiological dose-response curves. Am J Physiol 1978;235:E97-102.
48. Gennings C. On testing for drug/chemical interactions: definitions and inference. J Biopharm Stat 2000;10:457-67.
49. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000;20:205-12.
50. Liu W, Bodle E, Chen JY, et al. Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol 2001;25:111-8.